ACADIA Pharmaceuticals Inc. (ACAD)

Market Cap	2.92B
Revenue (ttm)	929.24M
Net Income (ttm)	128.51M
Shares Out	166.39M
EPS (ttm)	0.78
PE Ratio	22.63
Forward PE	34.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,137,188
Open	17.73
Previous Close	17.52
Day's Range	17.35 - 17.89
52-Week Range	14.15 - 29.29
Beta	0.37
Analysts	Buy
Price Target	26.17 (+48.95%)
Earnings Date	Feb 25, 2025

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin tha...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 27, 2004
• Employees: 598
• Stock Exchange: NASDAQ
• Ticker Symbol: ACAD
• Website: https://www.acadia.com

Financial Performance

In 2023, ACADIA Pharmaceuticals's revenue was $726.44 million, an increase of 40.45% compared to the previous year's $517.24 million. Losses were -$61.29 million, -71.62% less than in 2022.

Analyst Forecast

According to 19 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is $26.17, which is an increase of 48.95% from the latest price.

Price Target

$26.17

(48.95% upside)

Analyst Consensus: Buy